Canagliflozin and Metformin Extended-Release Tablets and Caprelsa
Determining the interaction of Canagliflozin and Metformin Extended-Release Tablets and Caprelsa and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Vandetanib may increase the blood levels and effects of metFORMIN. You may need a dose adjustment if you have been receiving metFORMIN and are starting treatment with vandetanib. Likewise, if you have been receiving both medications, the dose of metFORMIN may need to be adjusted if vandetanib is discontinued. Contact your doctor if your condition changes or you experience increased side effects. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with vandetanib may increase the plasma concentrations of drugs that are substrates of organic cation transporter 2 (OCT2). The mechanism is inhibition of OCT2-mediated renal tubular secretion by vandetanib. In healthy study subjects, single-dose coadministration of metformin and vandetanib increased metformin peak plasma concentration (Cmax) by 50% and systemic exposure (AUC) by 74%.
MANAGEMENT: Caution is advised when vandetanib is used with drugs that are substrates of OCT2, particularly those with a narrow therapeutic range such as metformin. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever vandetanib is added to or withdrawn from therapy.
- "Product Information. Vandetanib (vandetanib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.
- EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
Generic Name: canagliflozin / metformin
Brand name: Invokamet, Invokamet XR
Synonyms: Canagliflozin and metformin, Canagliflozin and Metformin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Canagliflozin and Metformin Extended-Release Tablets-Capreomycin
- Canagliflozin and Metformin Extended-Release Tablets-Capreomycin Injection
- Canagliflozin and Metformin Extended-Release Tablets-Capreomycin Sulfate
- Canagliflozin and Metformin Extended-Release Tablets-Capron DM
- Canagliflozin and Metformin Extended-Release Tablets-Capsagel
- Canagliflozin and Metformin Extended-Release Tablets-Capsagel Extra Strength
- Caprelsa-Canagliflozin and Metformin Tablets
- Caprelsa-Canakinumab
- Caprelsa-Canakinumab Subcutaneous
- Caprelsa-Canasa
- Caprelsa-Canasa Pac rectal
- Caprelsa-Canasa rectal